Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease-Reference-Cited by-同舟云学术

Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease

Published:2023-12-06 Issue:12 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

van Geffen Wouter H¹,Tan Daniel J²,Walters Julia AE³,Walters E Haydn⁴

Affiliation:

1. Department of Pulmonary Diseases; Medical Center Leeuwarden; Leeuwarden Netherlands

2. Allergy and Lung Health Unit, Melbourne School of Population and Global Health; University of Melbourne; Melbourne Australia

3. School of Medicine; University of Tasmania; Hobart Australia

4. NHMRC Centre of Research Excellence for Chronic Respiratory Disease; School of Medicine, University of Tasmania; Hobart Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Reference111 articles.

1. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial;Ferguson;Lancet Respiratory Medicine,2018

2. Once-daily single-inhaler triple versus dual therapy in patients with COPD;Lipson;New England Journal of Medicine,2018

3. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol;Pascoe;European Respiratory Journal,2016

4. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial;Papi;Lancet,2018

5. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6mug and 160/18/9.6mug using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol;Rabe;Respiratory Medicine,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival benefit of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a nationwide cohort study;Scientific Reports;2024-06-26

2. Inhaled corticosteroid treatment and pneumonia in patients with chronic obstructive pulmonary disease – nationwide development from 1998 to 2018;European Clinical Respiratory Journal;2024-05-29

3. Cochrane-Analyse: 3-fach-Therapie erfolgreich bei COPD, aber etwas häufigere Pneumonien;Deutsches Ärzteblatt Online;2024-05-17

4. Response;CHEST;2024-05

5. Pulmonology: What You May Have Missed in 2023;Annals of Internal Medicine;2024-05